Drug
Verteporfin clinical trials
Also written Visudyne and BPD-MA.
- studies test it
- 37
- open now
- 6
- in phase 3
- 5
- first study started
- 1994
Keep track of what changes. Save the Verteporfin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
37 studies that test it; most in 2007 (6)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2021 | 1 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 19
- Phase 3
- 5
- Phase 4
- 6
- No phase
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 27
Novartis (4) · Manhattan Eye, Ear & Throat Hospital (3) · Mayo Clinic (2) · QLT Inc. (2) · SpectraCure AB (2) · Oklahoma State University Center for Health Sciences (1) · University College, London (1) · Sun Yat-sen University (1)
Often tested with
Tested in the same studies.
Ranibizumab (7) · Dexamethasone (3) · Triamcinolone Acetonide (3) · Photodynamic Therapy (2) · Bevacizumab (2) · Aflibercept (2) · Pegaptanib (2) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses Verteporfin is read from its arms, and is right about nine times in ten.
Testing it · 37
- SCARFREE-001: Verteporfin for Scar PreventionNot yet recruitingPhase 2Odense University HospitalNCT07488988Written as Verteporfin Injection
- Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 SystemRecruitingPhase 1/2SpectraCure ABNCT06807359Written as Verteporfin Injection
- Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 SystemRecruitingPhase 1/2SpectraCure ABNCT03067051Written as Verteporfin
- Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway ObstructionRecruitingPhase 1/2Roswell Park Cancer InstituteNCT06306638Written as Verteporfin
- Effect of YAP1-inhibition in Surgical Wounds.Not yet recruitingPhase 1/2Jöri PüncheraNCT06944249Written as Verteporfin Injection
- Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated GlioblastomaRecruitingPhase 1/2Emory UniversityNCT04590664Written as Verteporfin
- Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingPhase 2Mayo ClinicNCT06381154Written as Verteporfin
- Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 StudyCompletedPhase 2Mayo ClinicNCT03033225Written as Verteporfin
- Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple TherapyWithdrawnPhase 4Wake Forest University Health SciencesNCT04075136Written as verteporfin
- Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular DegenerationCompletedPhase 4Oklahoma State University Center for Health SciencesNCT00473642Written as Verteporfin
- Photo-induction as a Means to Improve Cisplatin Delivery to Pleural MalignanciesTerminatedPhase 1Centre Hospitalier Universitaire VaudoisNCT02702700Written as Verteporfin
- An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast CancerStatus unknownPhase 2Rogers Sciences Inc.NCT02939274Written as Verteporfin
- Treatment of Primary Breast Cancer Using PDTCompletedNot applicableUniversity College, LondonNCT02872064Written as Verteporfin
- Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN RegimenCompletedNot applicableSun Yat-sen UniversityNCT03459144Written as verteporfin
- Cohort Study of the Clinical Course of Macular Diseases in KagawaStatus unknownPhase 4Kagawa UniversityNCT02321267Written as ranibizumab, aflibercept, pegaptanib, verteporphin
- Photodynamic Therapy for the Treatment of Vertebral MetastasesCompletedPhase 1Sunnybrook Health Sciences CentreNCT02464761Written as Visudyne
- Second Line Therapy to Treat Age-related Macular Degeneration (AMD) for Patients Not Responding Well to Lucentis Therapy by ItselfWithdrawnPhase 2Vitreous -Retina- Macula Consultants of New YorkNCT00457678Written as Visudyne
- A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in EyesTerminatedNot applicableNorwegian University of Science and TechnologyNCT01746875Written as Verteporfin
- ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot StudyStatus unknownNot applicableManhattan Eye, Ear & Throat HospitalNCT01974622Written as Visudyne
- Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain TumorsStatus unknownPhase 1Medical College of WisconsinNCT00002647Written as verteporfin
See all 37 studies that test Verteporfin →
Given in every arm · 3 — Verteporfin is usual care beside what is tested
- Ranibizumab and Reduced Fluence PDT for AMDCompletedPhase 2Texas Retina AssociatesNCT00527475Written as verteporfin
- Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMDWithdrawnNot applicableDuke UniversityNCT02457026Written as Verteporfin
- A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal PegaptanibCompletedPhase 3Novartis PharmaceuticalsNCT00242580Written as Verteporfin photodynamic therapy
As the comparator · 3 — what is tested is compared with Verteporfin
- Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic MyopiaCompletedPhase 3Novartis PharmaceuticalsNCT01922102Written as Verteporfin PDT
- VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)CompletedPhase 3BayerNCT01482910Written as Visudyne
- Ranibizumab Versus PDT for Presumed Ocular HistoplasmosisStatus unknownPhase 2Barnes Retina InstituteNCT00546936Written as verteporfin
Codes
What other systems call Verteporfin · ClinicalTrials.gg INT006709
- MeSH (NLM) D000077362VerteporfinConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 0X9PA28K43VERTEPORFINConfirmed FDA, NLM, Wikidata
- RxNorm 118886Confirmed FDA, Wikidata
- Wikidata Q782318verteporfinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1014VerteporfinConfirmed FDA, Wikidata
- DrugBank DB00460One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077362 | Verteporfin | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 0X9PA28K43 | VERTEPORFIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 118886 | — | Confirmed FDA, Wikidata |
| Wikidata | Q782318 | verteporfin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1014 | Verteporfin | Confirmed FDA, Wikidata |
| DrugBank | DB00460 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.